Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02586675
Title TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

Her2-receptor negative breast cancer

Therapies

Goserelin

Ribociclib + Tamoxifen

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.